Phaseline

Targets › CD8A

CD8A (T-cell surface glycoprotein CD8 alpha chain): drug programs, companies and trials

4 programs from 4 companies in 4 trials: 3 Phase 1, 1 Phase 2; Oncology, Neurology; next expected readout Jan 2027.

Integral membrane glycoprotein that plays an essential role in the immune response and serves multiple functions in responses against both external and internal offenses. In T-cells, functions primarily as a coreceptor for MHC class I molecule:peptide complex. (UniProt, P01732)

Open in Phaseline: the race on CD8A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University Medical Center Groningencrefmirlimab
anti-CD8 antibody for PET imaging
CD8APhase 2Locally Advanced Solid TumorNov 2028
Jonsson Comprehensive Cancer CenterZirconium Zr 89 Crefmirlimab Berdoxam
Radiolabeled anti-CD8+ minibody radioimmunoconjugate
CD8APhase 1GliomaJan 2027
City of Hope Medical CenterZirconium Zr 89-Df-Crefmirlimab
Anti-CD8 positron emission tomography imaging agent
CD8A, CD8BPhase 1Metastatic Malignant Solid NeoplasmOct 2027
National Institute of Neurological Disorders and Stroke (NINDS)89 Zr-Df-crefmirlimab
Anti-CD8+ minibody conjugated with deferoxamine and radiolabeled with Zr-89 for PET imagin
CD8APhase 1Progressive Multifocal LeukoencephalopathyApr 2030

Conditions

Locally Advanced Solid Tumor (1) Glioma (1) Metastatic Malignant Solid Neoplasm (1) Progressive Multifocal Leukoencephalopathy (1)

Modalities

antibody (3)

Companies

University Medical Center Groningen (1) Jonsson Comprehensive Cancer Center (1) City of Hope Medical Center (1) National Institute of Neurological Disorders and Stroke (NINDS) (1)

Related targets

CD8B (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.